Role of Ethnicity and Geographic Location on Glioblastoma IDH1/IDH2 Mutations.
作者： Yoshua Esquenazi , Quinn T. Ostrom , Nitin Tandon , Ping Zhu , Angel I. Blanco
DOI: 10.1016/J.WNEU.2021.01.079
关键词: Referral 、 Survival analysis 、 Population 、 Ethnic group 、 Oncology 、 Medicine 、 Internal medicine 、 Retrospective cohort study 、 IDH2 、 IDH1 、 Cancer registry
摘要: Background Previous studies have demonstrated possible differences in glioblastoma (GBM) survival attributable to ethnicity. The goal of this study was quantify oncogenic and evaluate the overall (OS) progression-free (PFS) GBM patients across race/ethnicity using both population-based surveillance institutional data sets from United States (US) Mexico. Methods Retrospective cohort comprising Texas Cancer Registry (TCR, n = 4134) referral institutions located US (n 254) Mexico 47) were evaluated. Primary outcomes include OS PFS. Oncogenic ethnicity assessed. IDH1/IDH2 status evaluated by sequencing samples. Kaplan-Meier Cox proportional hazards regression for analysis. Results A total 4134 identified TCR set, comparison that Hispanic diagnosed at a significantly younger age compared non-Hispanic white (NHW) (median: 58 vs. 62, P Conclusions IDH2 mutations are more prevalent Mexican individuals may be crucial contributor previously reported benefit large population databases. These findings critical screening targeted interventions GBM.
sci-hub.st 参考文章(47)
Jacqueline Benedetti, John Crowley, Stephanie Green, Clinical Trials in Oncology ,(1997)
Matthew J. McGirt, Khoi D. Than, Jon D. Weingart, Kaisorn L. Chaichana, Frank J. Attenello, Alessandro Olivi, John Laterra, Lawrence R. Kleinberg, Stuart A. Grossman, Henry Brem, Alfredo Quiñones-Hinojosa, Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme Journal of Neurosurgery. ,vol. 110, pp. 583- 588 ,(2009) , 10.3171/2008.5.17557
Courtney D. DiNardo, Farhad Ravandi, Sam Agresta, Marina Konopleva, Koichi Takahashi, Tapan Kadia, Mark Routbort, Keyur P. Patel, Mark Brandt, Sherry Pierce, Guillermo Garcia-Manero, Jorge Cortes, Hagop Kantarjian, Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML American Journal of Hematology. ,vol. 90, pp. 732- 736 ,(2015) , 10.1002/AJH.24072
Luisa N. Borrell, Natalie D. Crawford, All-Cause Mortality Among Hispanics in the United States : Exploring Heterogeneity by Nativity Status, Country of Origin, and Race in the National Health Interview Survey-Linked Mortality Files Annals of Epidemiology. ,vol. 19, pp. 336- 343 ,(2009) , 10.1016/J.ANNEPIDEM.2008.12.003
Wei Yan, Wei Zhang, Gan You, Zhaoshi Bao, Yongzhi Wang, Yanwei Liu, Chunsheng Kang, Yongping You, Lei Wang, Tao Jiang, None, Correlation of IDH1 Mutation with Clinicopathologic Factors and Prognosis in Primary Glioblastoma: A Report of 118 Patients from China PLoS ONE. ,vol. 7, pp. e30339- ,(2012) , 10.1371/JOURNAL.PONE.0030339
Doo-Sik Kong, Jung-Il Lee, Kwan Park, Jong Hyun Kim, Do-Hoon Lim, Do-Hyun Nam, Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas Cancer. ,vol. 112, pp. 2046- 2051 ,(2008) , 10.1002/CNCR.23402
Michel Lacroix, Dima Abi-Said, Daryl R Fourney, Ziya L Gokaslan, Weiming Shi, Franco DeMonte, Frederick F Lang, Ian E McCutcheon, Samuel J Hassenbusch, Eric Holland, Kenneth Hess, Christopher Michael, Daniel Miller, Raymond Sawaya, None, A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival Journal of Neurosurgery. ,vol. 95, pp. 190- 198 ,(2001) , 10.3171/JNS.2001.95.2.0190
Wolfgang Wick, Christian Hartmann, Corinna Engel, Mandy Stoffels, Jörg Felsberg, Florian Stockhammer, Michael C. Sabel, Susanne Koeppen, Ralf Ketter, Richard Meyermann, Marion Rapp, Christof Meisner, Rolf D. Kortmann, Torsten Pietsch, Otmar D. Wiestler, Ulrike Ernemann, Michael Bamberg, Guido Reifenberger, Andreas von Deimling, Michael Weller, NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide Journal of Clinical Oncology. ,vol. 27, pp. 5874- 5880 ,(2009) , 10.1200/JCO.2009.23.6497
Roger Stupp, Warren P. Mason, Martin J. van den Bent, Michael Weller, Barbara Fisher, Martin J.B. Taphoorn, Karl Belanger, Alba A. Brandes, Christine Marosi, Ulrich Bogdahn, Jürgen Curschmann, Robert C. Janzer, Samuel K. Ludwin, Thierry Gorlia, Anouk Allgeier, Denis Lacombe, J. Gregory Cairncross, Elizabeth Eisenhauer, René O. Mirimanoff, Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma The New England Journal of Medicine. ,vol. 352, pp. 987- 996 ,(2005) , 10.1056/NEJMOA043330
Manfred Westphal, Dana C. Hilt, Enoch Bortey, Patrick Delavault, Robert Olivares, Peter C. Warnke, Ian R. Whittle, Juha Jääskeläinen, Zvi Ram, A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology. ,vol. 5, pp. 79- 88 ,(2003) , 10.1093/NEUONC/5.2.79